Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

ANTX vs EBS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ANTX Captures Overall Composite Edge (37.2 SELL vs 42.6 HOLD), While EBS Leads 4–2 on Growth & Valuation Pillars

ANTX Overall Winner 6-Pillar Tally: ANTX 2 – 4 EBS Matrix Metrics: ANTX 4 – 6 EBS

As of Nov 19, 2026, AN2 Therapeutics, Inc. (ANTX) captures the overall head-to-head institutional edge over Emergent Biosolutions, Inc. (EBS) on higher Unified Composite conviction (37.2/100 SELL vs. 42.6/100 HOLD) after splitting the core matrix 4–6 (led by Growth & Scale, Options & Positioning), while EBS wins 4–2 across the 6-pillar growth and valuation breakdown. ANTX trades at $5.22 (N/M Forward P/E, 0.0% operating margin) versus EBS at $5.15 (19.3x Forward P/E, 5.8% operating margin).

  • Composite vs. Pillar Nuance: While EBS currently prints a higher short-term Unified Composite Score (42.6/100 HOLD vs. ANTX 37.2/100 SELL), ANTX captures the overall institutional head-to-head verdict (4–6 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 5.8% operating margin) and revenue trajectory (+0.0% vs. -52.4% YoY).
  • Technical & Structure Timing Caution: ANTX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 65.0); meanwhile EBS is in a Breakdown options structure phase (RSI 29.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ANTX vs EBS
ANTX NASDAQ Head-to-Head Winner
AN2 Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$5.22
+5.45% 1D
Market Cap $190.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.75β · 98% Vol
Unified Composite Score
37.2 / 100 SELL
Tech 15.0 Fund 39.0 Flow 69.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 65
RSI-14: 65.0 · SMA20: $4.31 · SMA50: $4.52
EBS NYSE
Emergent Biosolutions, Inc.
Pharmaceutical Preparations
$5.15
-6.36% 1D
Market Cap $282.8M
TTM Revenue $649M
Forward P/E 19.3x
Beta / 30D Vol 0.90β · 54% Vol
Unified Composite Score
42.6 / 100 HOLD
Tech 25.0 Fund 51.0 Flow 67.0 Mom 59.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 29
RSI-14: 29.2 · SMA20: $6.14 · SMA50: $6.47

6-Pillar Scorecard Institutional Category Breakdown (ANTX 2 – 4 EBS)

Columns: Metric · ANTX · EBS
1. Valuation Multiples EBS
Forward P/E N/M 19.3x
Trailing P/E N/M 19.3x
PEG Ratio N/M 0.38x
EV / Revenue N/M 0.9x
2. Growth & Scale ANTX
Revenue Growth (YoY) +0.0% -52.4%
Earnings Growth (YoY) +0.0% -93.8%
TTM Revenue (USD) N/A $649M
Market Cap $190.1M $282.8M
3. Profitability & Quality EBS
Gross Margin N/A 43.4%
Operating Margin 0.0% 5.8%
Net Profit Margin 0.0% -40.2%
Return on Equity (ROE) -51.3% -58.2%
4. Balance Sheet & Cash Flow EBS
Cash Generation (TTM) -$30M $188M
Cash Flow Margin N/A 29.0%
Net Cash / Leverage $1.99 Book/Sh · -51.3% ROE $332M Net Debt (1.62x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ANTX
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 134.2% (22nd %ile) 84.5% (5th %ile)
Put/Call OI Skew N/A 2.48x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat EBS
OpEx & R&D Intensity N/A 37.6% of Rev ($244M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ANTX (4) vs EBS (6)
Institutional Metric ANTX EBS Criterion Row Edge
Market Capitalization
Scale
$190.1M $282.8M Larger Scale EBS
Trailing P/E Ratio
Valuation
N/M 19.3x Lower Multiple EBS
Forward P/E Ratio
Valuation
N/M 19.3x Lower Multiple EBS
Revenue Growth (YoY)
Growth
+0.0% -52.4% Higher Growth ANTX
Operating Margin (TTM)
Profitability
0.0% 5.8% Higher Margin EBS
Net Profit Margin
Profitability
0.0% -40.2% Higher Margin ANTX
Return on Equity (ROE)
Capital Efficiency
-51.3% -58.2% Higher ROE ANTX
52-Week Range Position
Momentum
68% ($1–$7) 8% ($4–$14) Stronger Trend ANTX
Beta / 30D Volatility
Risk Regime
0.75β · 98% Vol 0.90β · 54% Vol Lower Realized Risk EBS
Unified Institutional Score
Composite Signal
37.2 / 100 (SELL) 42.6 / 100 (HOLD) Higher Composite EBS
Trailing 12M Revenue (USD)
Operating Scale
N/A $649M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 43.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 0.38x PEG · 0.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$30M ($1.99 Book/Sh · -51.3% ROE) $188M ($332M Net Debt (1.62x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ANTX +61.94 pp
ANTX: +45.0% · EBS: -16.94%
3M Horizon EBS +11.53 pp
ANTX: -10.15% · EBS: +1.38%
6M Horizon ANTX +45.22 pp
ANTX: +6.75% · EBS: -38.47%
1Y Horizon ANTX +415.18 pp
ANTX: +366.07% · EBS: -49.11%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANTX vs EBS. Trailing 12-month operating profitability (ANTX 0.0% vs EBS 5.8%) and valuation multiples (ANTX N/M vs EBS 19.3x Forward P/E) are benchmarked directly in Pillar 4 below.

ANTX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-51.3% · N/M
EBS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$649M
Gross Margin43.4%
Op. Margin5.8%
ROE / Fwd P/E-58.2% · 19.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ANTX CONSOLIDATION
177d in phase · OBV NEUTRAL
Current IV 134.2%
IV Percentile 22nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ANTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EBS BREAKDOWN
33d in phase · OBV DISTRIBUTION
Current IV 84.5%
IV Percentile 5th %ile
Put/Call OI Skew 2.48x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact EBS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $5.81 · IV 78.8%

EBS Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($581)

Compare $581 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 78.8% ATM IV.

5-DAY BULLISH SWING Liq C

Dec 18 $6 / $7 Bull Call Spread

Buy 4x $6C · Sell 4x $7C · 32d

Net Entry $180 Debit
T+5d @ +5% Move +$21 (+12%)
Max Risk / Buffer $180 Capped
5d Edge & Liquidity 0.4x R:R · Liq C
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq C

Dec 18 $5P / $6-$7C Seagull

Sell 2x $5P · Buy 2x $6/$7C · 32d

Net Entry $60 Debit
T+5d @ +5% Move +$27 (+14.0% RoM)
Max Risk / Buffer -13.9% Put Cushion ($190 Mgn)
5d Edge & Liquidity 0.7x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ANTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $190.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
EBS Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $282.8M market capitalization and 5.8% operating margin.
OpEx & R&D Reinvestment 37.6% of Rev ($244M)
90D Engineering Disclosures 0 Published

Investor FAQ ANTX vs EBS Key Questions & Quantitative Answers

As of Nov 19, 2026, AN2 Therapeutics, Inc. (ANTX) captures the overall head-to-head institutional edge over Emergent Biosolutions, Inc. (EBS) on higher Unified Composite conviction (37.2/100 SELL vs. 42.6/100 HOLD) after splitting the core matrix 4–6 (led by Growth & Scale, Options & Positioning), while EBS wins 4–2 across the 6-pillar growth and valuation breakdown. ANTX trades at $5.22 (N/M Forward P/E, 0.0% operating margin) versus EBS at $5.15 (19.3x Forward P/E, 5.8% operating margin). Composite vs. Pillar Nuance: While EBS currently prints a higher short-term Unified Composite Score (42.6/100 HOLD vs. ANTX 37.2/100 SELL), ANTX captures the overall institutional head-to-head verdict (4–6 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 5.8% operating margin) and revenue trajectory (+0.0% vs. -52.4% YoY). Technical & Structure Timing Caution: ANTX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 65.0); meanwhile EBS is in a Breakdown options structure phase (RSI 29.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ANTX leads the Growth & Scale pillar: ANTX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with EBS at -52.4% YoY revenue growth and -93.8% YoY earnings growth on $649M TTM revenue (43.4% gross margin, 5.8% operating margin). On trailing 12-month operating scale, ANTX generates N/A in USD-normalized revenue versus $649M for EBS. In operating R&D and SG&A reinvestment, ANTX deploys N/A (0 90-day corporate R&D disclosures) versus 37.6% of Rev ($244M) (0 disclosures) for EBS.

EBS screens cheaper on headline valuation multiples. ANTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas EBS trades at 19.3x Forward P/E, 19.3x Trailing P/E, 0.38x PEG, and 0.9x EV/Revenue (29.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ANTX (-51.3% ROE) versus EBS (-58.2% ROE) capital efficiency.

In options market volatility and institutional positioning, ANTX carries 134.2% implied volatility (22nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.75β · 98% Vol realized risk). By comparison, EBS carries 84.5% implied volatility (5th %ile, Compressed (<25th %ile)), a 2.48x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.90β · 54% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.